title: Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.
abstract: Hematologic malignancies provide a suitable testing environment for cell-based immunotherapies, which were pioneered by the development of allogeneic hematopoietic stem cell transplant. All types of cell-based therapies, from donor lymphocyte infusion to dendritic cell vaccines, and adoptive transfer of tumor-specific cytotoxic T cells and natural killer cells, have been clinically translated for hematologic malignancies. The recent success of chimeric antigen receptor-modified T lymphocytes in B-cell malignancies has stimulated the development of this approach toward other hematologic tumors. Similarly, the remarkable activity of checkpoint inhibitors as single agents has created enthusiasm for potential combinations with other cell-based immune therapies. However, tumor cells continuously develop various strategies to evade their immune-mediated elimination. Meanwhile, the recruitment of immunosuppressive cells and the release of inhibitory factors contribute to the development of a tumor microenvironment that hampers the initiation of effective immune responses or blocks the functions of immune effector cells. Understanding how tumor cells escape from immune attack and favor immunosuppression is essential for the improvement of immune cell-based therapies and the development of rational combination approaches.
authors.affiliation: Lineberger Comprehensive Cancer Center.
authors.forename: Chuang
authors.initials: C
authors.lastname: Sun
authors.affiliation: Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, and.
authors.forename: Gianpietro
authors.initials: G
authors.lastname: Dotti
authors.affiliation: Lineberger Comprehensive Cancer Center, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
authors.forename: Barbara
authors.initials: B
authors.lastname: Savoldo
mesh_terms: D019264:Adoptive Transfer / Q000379:methods*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D019337:Hematologic Neoplasms / Q000276:immunology / Q000628:therapy; D006801:Humans; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology; D019139:Tumor Escape
chemical_list: D011948:Receptors, Antigen, T-Cell